Incyte Corporation (0J9P.L)
0J9P.L Stock Price Chart
Explore Incyte Corporation interactive price chart. Choose custom timeframes to analyze 0J9P.L price movements and trends.
0J9P.L Company Profile
Discover essential business fundamentals and corporate details for Incyte Corporation (0J9P.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
2.62K
Website
https://www.incyte.comCEO
Herve Hoppenot
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
0J9P.L Financial Timeline
Browse a chronological timeline of Incyte Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 27 Oct 2025
Upcoming earnings on 28 Jul 2025
Revenue estimate is $1.15B.
Earnings released on 29 Apr 2025
EPS came in at $0.80 falling short of the estimated $0.98 by -18.40%, while revenue for the quarter reached $1.05B, missing expectations by -8.28%.
Earnings released on 10 Feb 2025
EPS came in at $1.02 falling short of the estimated $1.50 by -32.00%, while revenue for the quarter reached $1.18B, beating expectations by +17.03%.
Earnings released on 29 Oct 2024
EPS came in at $0.54 falling short of the estimated $1.05 by -48.19%, while revenue for the quarter reached $1.14B, beating expectations by +5.53%.
Earnings released on 30 Jul 2024
EPS came in at -$2.04 falling short of the estimated $0.75 by -372.44%, while revenue for the quarter reached $1.04B, beating expectations by +2.85%.
Earnings released on 30 Apr 2024
EPS came in at $0.75 falling short of the estimated $0.78 by -4.73%, while revenue for the quarter reached $880.89M, missing expectations by -4.45%.
Earnings released on 11 Mar 2024
EPS came in at $0.89 falling short of the estimated $1.15 by -22.70%, while revenue for the quarter reached $1.01B, beating expectations by +1.06%.
Earnings released on 12 Dec 2023
EPS came in at $0.76 falling short of the estimated $0.83 by -9.23%, while revenue for the quarter reached $919.03M, missing expectations by -4.63%.
Earnings released on 1 Aug 2023
EPS came in at $0.90 surpassing the estimated $0.70 by +29.60%, while revenue for the quarter reached $954.61M, beating expectations by +4.94%.
Earnings released on 2 May 2023
EPS came in at $0.10 falling short of the estimated $0.56 by -82.82%, while revenue for the quarter reached $808.67M, missing expectations by -5.88%.
Earnings released on 7 Feb 2023
EPS came in at $0.13 falling short of the estimated $0.30 by -57.80%, while revenue for the quarter reached $926.70M, beating expectations by +5.52%.
Earnings released on 30 Sept 2022
EPS came in at $0.50 falling short of the estimated $0.50 by -0.20%, while revenue for the quarter reached $823.30M, missing expectations by -2.30%.
Earnings released on 30 Jun 2022
EPS came in at $0.72 surpassing the estimated $0.56 by +28.70%, while revenue for the quarter reached $911.40M, beating expectations by +11.35%.
Earnings released on 31 Mar 2022
EPS came in at $0.17 falling short of the estimated $0.46 by -62.63%, while revenue for the quarter reached $733.24M, missing expectations by -2.23%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 7 Feb 2022
EPS came in at $2.54 surpassing the estimated $0.56 by +352.76%, while revenue for the quarter reached $862.85M, beating expectations by +6.20%.
Earnings released on 2 Nov 2021
EPS came in at $0.67, while revenue for the quarter reached $705.71M.
Earnings released on 30 Sept 2021
EPS came in at $0.82, while revenue for the quarter reached $812.99M.
Earnings released on 31 Mar 2021
EPS came in at $0.24, while revenue for the quarter reached $604.72M.
Earnings released on 31 Dec 2020
EPS came in at $0.68, while revenue for the quarter reached $789.51M.
Earnings released on 30 Sept 2020
EPS came in at -$0.07, while revenue for the quarter reached $620.64M.
0J9P.L Stock Performance
Access detailed 0J9P.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.